Koen Kas
Profile
Koen Kas is the founder of MyCartis NV, which was founded in 2004.
He held the title of Director & Chief Scientific Officer from 2009 to 2011.
Dr. Kas also held former positions as Director-Drug Discovery at Galapagos Genomics NV, Principal at Tibotec Virco NV and Virco Group NV, Chief Scientific Officer-Oncology at Oxurion NV, and Professor at Harvard University and Université Catholique de Louvain.
Dr. Kas received his undergraduate and doctorate degrees from the University of Antwerp.
Former positions of Koen Kas
| Companies | Position | End |
|---|---|---|
| Université Catholique de Louvain | Corporate Officer/Principal | - |
| OXURION NV | Chief Tech/Sci/R&D Officer | 2013-01-15 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| Virco Group NV | Corporate Officer/Principal | - |
Tibotec Virco NV
 Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Corporate Officer/Principal | - |
Training of Koen Kas
| University of Antwerp | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| OXURION NV | Health Technology |
| Private companies | 4 |
|---|---|
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Commercial Services |
| Virco Group NV | Commercial Services |
- Stock Market
- Insiders
- Koen Kas
